1 Regarding &quot;Postresection Period-Specific Hazard of Recurrence as a Framework for Surveillance Strategy in Patients with Hepatocellular Carcinoma: A Multicenter Outcome Study&quot;

2 Adjuvant therapy of pancreatic carcinoma: the experience of Policlinico Umberto I, Universit&agrave; &quot;Sapienza&quot; Rome

3 Histopathologic Predictors of Survival and Recurrence in Resected Ampullary Adenocarcinoma: International Multicenter Cohort Study.

4 Oncologic outcomes of minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.

5 Acute Renal Transplant Failure Secondary to an Obstructing Ileal Conduit Adenocarcinoma: Case Report and Literature Review.

6 Prognostic profile of patients with non-viral hepatocellular carcinoma: A comparative study with hepatitis C virus-related hepatocellular carcinoma using data mining analysis.

7 Targeting hepatocellular carcinoma: Synthesis of new pyrazole-based derivatives, biological evaluation, DNA binding, and molecular modeling studies

8 Intermediate stage hepatocellular carcinoma: a summary review

9 Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives

10 Road map for fibrolamellar carcinoma: progress and goals of a diversified approach

11 Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date

12 Hepatocellular carcinoma: a review of diagnostic challenges for the pathologist

13 Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review

14 Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies

15 Hepatocellular carcinoma: early-stage management challenges

16 Screening for hepatocellular carcinoma: patient selection and perspectives

17 Irreversible electroporation of hepatocellular carcinoma: patient selection and perspectives

18 Needle track seeding after radiofrequency ablation for hepatocellular carcinoma: prevalence, impact, and management challenge

19 Pediatric hepatocellular carcinoma: challenges and solutions

20 Surgical resection of localized hepatocellular carcinoma: patient selection and special consideration

21 Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date

22 GPC-3 in hepatocellular carcinoma: current perspectives

23 Hepatocellular carcinoma: a review

24 Transarterial radioembolization for hepatocellular carcinoma: a review

25 Fibrolamellar hepatocellular carcinoma: current clinical perspectives

26 Transarterial chemoembolization for hepatocellular carcinoma: an evidence-based review of its place in therapy

27 Chemoembolization with drug-eluting microspheres (DEM-TACE) for hepatocellular carcinoma: single-center review of safety and efficacy

28 Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments

29 Hepatocellular carcinoma: epidemiology and risk factors

30 Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives

31 Intensity-modulated carbon-ion radiation therapy versus intensity-modulated photon-based radiation therapy in locally recurrent nasopharyngeal carcinoma: a dosimetric comparison

32 Intensity-modulated carbon-ion radiation therapy versus intensity-modulated photon-based radiation therapy in locally recurrent nasopharyngeal carcinoma: a dosimetric comparison

33 Intensity-modulated carbon-ion radiation therapy versus intensity-modulated photon-based radiation therapy in locally recurrent nasopharyngeal carcinoma: a dosimetric comparison

34 Molecular Biomarkers Related to Oral Carcinoma: Clinical Trial Outcome Evaluation in a Literature Review

35 Intermediate stage hepatocellular carcinoma: a summary review

36 Targeting myeloid-derived suppressor cells in the treatment of hepatocellular carcinoma: current state and future perspectives

37 Road map for fibrolamellar carcinoma: progress and goals of a diversified approach

38 Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date

39 Hepatocellular carcinoma: a review of diagnostic challenges for the pathologist

40 Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review

41 Targeted therapy and personalized medicine in hepatocellular carcinoma: drug resistance, mechanisms, and treatment strategies

42 Hepatocellular carcinoma: early-stage management challenges

43 Screening for hepatocellular carcinoma: patient selection and perspectives

44 Irreversible electroporation of hepatocellular carcinoma: patient selection and perspectives

45 Needle track seeding after radiofrequency ablation for hepatocellular carcinoma: prevalence, impact, and management challenge

46 Pediatric hepatocellular carcinoma: challenges and solutions

47 Surgical resection of localized hepatocellular carcinoma: patient selection and special consideration

48 Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date

49 GPC-3 in hepatocellular carcinoma: current perspectives

50 Hepatocellular carcinoma: a review

51 Transarterial radioembolization for hepatocellular carcinoma: a review

52 Fibrolamellar hepatocellular carcinoma: current clinical perspectives

53 Transarterial chemoembolization for hepatocellular carcinoma: an evidence-based review of its place in therapy

54 Chemoembolization with drug-eluting microspheres (DEM-TACE) for hepatocellular carcinoma: single-center review of safety and efficacy

55 Transarterial radioembolization using yttrium-90 microspheres in the treatment of hepatocellular carcinoma: a review on clinical utility and developments

56 Hepatocellular carcinoma: epidemiology and risk factors

57 Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives

58 Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial.

59 Inflammatory cytokines and combined biomarker panels in pancreatic ductal adenocarcinoma: Enhancing diagnostic accuracy.

60 A global view of hepatocellular carcinoma: trends, risk, prevention and management.

61 Hepatocellular carcinoma: Implications for Asia-Pacific Oncology Nurses

62 Radiomics in hepatocellular carcinoma: a quantitative review.

63 Clear cell renal cell carcinoma: validation of World Health Organization/International Society of Urological Pathology grading.

64 Mucoepidermoid Carcinoma: A Comparison of Histologic Grading Systems and Relationship to MAML2 Rearrangement and Prognosis.

65 Spatial and temporal heterogeneity of panel-based tumor mutational burden (TMB) in pulmonary adenocarcinoma: separating biology from technical artifacts.

66 Efficacy and safety of sorafenib versus apatinib in the treatment of intermediate and advanced hepatocellular carcinoma: a comparative retrospective study

67 Precision Adjuvant Therapy Based on Detailed Pathological Risk Factors for Resected Oral Cavity Squamous Cell Carcinoma: Long Term Outcome Comparison of CGMH and NCCN Guidelines.

68 Identification of key DNA methylation-driven genes in prostate adenocarcinoma: an integrative analysis of TCGA methylation data.

69 Chinese nonmedicinal herbal diet and risk of nasopharyngeal carcinoma: A population-based case-control study.

70 Risk of developing sudden sensorineural hearing loss in patients with nasopharyngeal carcinoma: A population-based cohort study

71 Radiation-induced hypoglossal nerve palsy after definitive radiotherapy for nasopharyngeal carcinoma: Clinical predictors and dose-toxicity relationship.

72 First-in-human phase I clinical trial of a combined immune modulatory approach using TetMYB vaccine and Anti-PD-1 antibody in patients with advanced solid cancer including colorectal or adenoid cystic carcinoma: The MYPHISMO study protocol (NCT03287427)

73 Postoperative outcomes in elderly patients undergoing pancreatic resection for pancreatic adenocarcinoma: A systematic review and meta-analysis.

74 Incidental abdominal lymph node metastases from a known breast cancer in resected specimen of invasive pancreatic ductal adenocarcinoma: report of a case.

75 The oncological safety in minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma: a systematic review and meta-analysis

76 Bevacizumab Demonstrates Prolonged Disease Stabilization in Patients with Heavily Pretreated Metastatic Renal Cell Carcinoma: A Case Series and Review of the Literature

77 Phospholipids are A Potentially Important Source of Tissue Biomarkers for Hepatocellular Carcinoma: Results of a Pilot Study Involving Targeted Metabolomics.

78 The CANLPH Score, an Integrative Model of Systemic Inflammation and Nutrition Status (SINS), Predicts Clinical Outcomes After Surgery in Renal Cell Carcinoma: Data From a Multicenter Cohort in Japan

79 Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values.

80 Active Surveillance of Papillary Thyroid Microcarcinoma: Where Do We Stand?

81 Outcomes of Elective and Emergency Conversion in Minimally Invasive Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: An International Multicenter Propensity Score-matched Study.

82 Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice

83 Aristolochic Acid and Immunotherapy for Urothelial Carcinoma: Directions for unmet Needs.

84 Efficacy and safety of sorafenib-gemcitabine combination therapy in advanced hepatocellular carcinoma: an open-label Phase II feasibility study.

85 Sequential transcatheter arterial chemoembolization and portal vein embolization versus portal vein embolization alone before major hepatectomy for patients with large hepatocellular carcinoma: An intent-to-treat analysis

86 Giant cystic brain metastasis from ovarian papillary serous adenocarcinoma: Case report and review of the literature

87 Cytopathology of Xp11 translocation renal cell carcinoma: a report of 5 cases.

88 Laparoscopic liver resection versus open liver resection for intrahepatic cholangiocarcinoma: 3-year outcomes of a cohort study with propensity score matching

89 First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial

90 Sex determining region Y-box 2 is a prognostic factor for head and neck squamous cell carcinoma: Evidence from 11 published investigations

91 Role of tumor markers in oral squamous cell carcinoma: Review of literature and future consideration

92 Comparative evaluation of survivin expression in leukoplakia, lichen planus, and oral squamous cell carcinoma: An immunohistochemical study

93 Systematic Pelvic Lymphadenectomy vs No Lymphadenectomy in Early-Stage Endometrial Carcinoma: Randomized Clinical Trial

94 Knowing the unknown in oral squamous cell carcinoma: An observational study

95 Knowing the unknown in oral squamous cell carcinoma: An observational study

96 Early esophageal carcinoma: endoscopic ultrasonography using the sonoprobe

97 Endoscopic nasopharyngectomy for salvage in nasopharyngeal carcinoma: a novel anatomic orientation

98 Comparative evaluation of survivin expression in leukoplakia, lichen planus, and oral squamous cell carcinoma: An immunohistochemical study

99 Sex determining region Y-box 2 is a prognostic factor for head and neck squamous cell carcinoma: Evidence from 11 published investigations

100 hepatocellular carcinoma: early-stage management challenges

101 nasopharyngeal adenoid cystic carcinoma: report of five cases and treatment outcome

Keyword Connections

Journals

Research Groups

Bibliographies